CN Patent
CN1871003B — 3-(4-氨基-1-氧代-1,3二氢-异吲哚-2-基)-哌啶-2,6-二酮的多晶型物
Assigned to Celgene Corp · Expires 2012-03-14 · 14y expired
What this patent protects
公开了3-(4-氨基-1-氧代-1,3二氢-异吲哚-2-基)-哌啶-2,6-二酮的多晶型物。还公开了含有这种多晶型物的组合物,制备这种多晶型物的方法以及其使用方法。
USPTO Abstract
公开了3-(4-氨基-1-氧代-1,3二氢-异吲哚-2-基)-哌啶-2,6-二酮的多晶型物。还公开了含有这种多晶型物的组合物,制备这种多晶型物的方法以及其使用方法。
Drugs covered by this patent
- Revlimid (lenalidomide) · Bristol-Myers Squibb
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.